These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26108882)

  • 21. Treatments of peptic ulcer.
    Baron JH
    Mt Sinai J Med; 2000 Jan; 67(1):63-7. PubMed ID: 10677784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease.
    Howden CW; Leontiadis GI
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):401-12. PubMed ID: 11403535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new class of quinazoline-sulfonamides acting as efficient inhibitors against the α-carbonic anhydrase from Trypanosoma cruzi.
    Alafeefy AM; Ceruso M; Al-Jaber NA; Parkkila S; Vermelho AB; Supuran CT
    J Enzyme Inhib Med Chem; 2015; 30(4):581-5. PubMed ID: 25373503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers].
    Imaizumi H; Koizumi W; Nakai H; Tanabe S; Ohida M; Saigenji K
    Nihon Rinsho; 1999 Jan; 57(1):167-72. PubMed ID: 10036957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective Inhibition of
    Grande R; Carradori S; Puca V; Vitale I; Angeli A; Nocentini A; Bonardi A; Gratteri P; Lanuti P; Bologna G; Simeone P; Capasso C; De Luca V; Supuran CT
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769015
    [No Abstract]   [Full Text] [Related]  

  • 28. [Current locally acting agents in the treatment of peptic ulcer].
    Ryss ES
    Klin Med (Mosk); 1986 Aug; 64(8):18-27. PubMed ID: 2878103
    [No Abstract]   [Full Text] [Related]  

  • 29. The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
    Vullo D; Luca VD; Scozzafava A; Carginale V; Rossi M; Supuran CT; Capasso C
    Bioorg Med Chem; 2013 Mar; 21(6):1534-8. PubMed ID: 22883029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy of peptic ulcer in the elderly].
    Koop H
    Z Gerontol; 1992; 25(5):304-8. PubMed ID: 1359717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Helicobacter pylori eradication therapy in cirrhotic patients with peptic ulcer disease.
    Mitrică D; Pleşa A; Constantinescu R; Drug V; Stanciu C
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):367-74. PubMed ID: 21870725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salts of 5-amino-2-sulfonamide-1,3,4-thiadiazole, a structural and analog of acetazolamide, show interesting carbonic anhydrase inhibitory properties, diuretic, and anticonvulsant action.
    Diaz JR; Camí GE; Liu-González M; Vega DR; Vullo D; Juárez A; Pedregosa JC; Supuran CT
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1102-10. PubMed ID: 26497704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Helicobacter pylori-negative peptic ulcers: frequency and implications for management.
    Freston JW
    J Gastroenterol; 2000; 35 Suppl 12():29-32. PubMed ID: 10779214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical characterization of recombinant β-carbonic anhydrase (PgiCAb) identified in the genome of the oral pathogenic bacterium Porphyromonas gingivalis.
    Del Prete S; Vullo D; De Luca V; AlOthman Z; Osman SM; Supuran CT; Capasso C
    J Enzyme Inhib Med Chem; 2015 Jun; 30(3):366-70. PubMed ID: 25032746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetazolamide for the treatment of idiopathic intracranial hypertension.
    Supuran CT
    Expert Rev Neurother; 2015; 15(8):851-6. PubMed ID: 26154918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for acid/peptic disorders.
    Schubert ML
    Yale J Biol Med; 1996; 69(2):197-201. PubMed ID: 9112751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Future perspectives of ulcer therapy].
    Garner A
    Ther Umsch; 1992 Nov; 49(11):782-7. PubMed ID: 1475774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
    Eminoğlu A; Vullo D; Aşık A; Çolak DN; Çanakçı S; Beldüz AO; Supuran CT
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1821-6. PubMed ID: 26920803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
    Prete SD; Vullo D; Osman SM; Scozzafava A; AlOthman Z; Capasso C; Supuran CT
    Bioorg Med Chem; 2014 Sep; 22(17):4537-43. PubMed ID: 25129169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.